SUTRO BIOPHARMA, INC. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
SUTRO BIOPHARMA, INC. (STRO) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $25.90 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2025-11-06
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $25.90M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $112.00M.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $124.10M.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $69.90M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2025-09-30 | $25.90M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $112.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $124.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $69.90M 10-Q · filed 2025-11-06 |
| 2024-09-30 | $56.70M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $287.60M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $190.50M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $110.90M 10-K · filed 2025-03-13 |
| 2023-09-30 | $56.90M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $26.40M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $68.50M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $139.50M 10-K · filed 2024-03-25 |
| 2022-09-30 | $137.20M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $98.40M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $138.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $176.50M 10-K · filed 2023-03-30 |
| 2020-12-31 | $14.70M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |